DarioHealth (NASDAQ:DRIO) Issues Earnings Results

DarioHealth (NASDAQ:DRIOGet Rating) issued its earnings results on Monday. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.03, MarketWatch Earnings reports. DarioHealth had a negative return on equity of 76.90% and a negative net margin of 301.07%. During the same quarter in the previous year, the company earned ($0.99) EPS.

DarioHealth Price Performance

Shares of DarioHealth stock traded down $0.17 on Wednesday, hitting $5.69. 2,270 shares of the company’s stock traded hands, compared to its average volume of 226,080. The company has a fifty day moving average of $6.15 and a two-hundred day moving average of $6.45. The company has a market capitalization of $130.07 million, a price-to-earnings ratio of -1.56 and a beta of 1.23. DarioHealth has a one year low of $4.11 and a one year high of $19.39.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in DarioHealth by 5.4% in the first quarter. Vanguard Group Inc. now owns 272,997 shares of the company’s stock worth $1,594,000 after buying an additional 14,033 shares during the last quarter. Nantahala Capital Management LLC increased its holdings in DarioHealth by 21.6% during the 1st quarter. Nantahala Capital Management LLC now owns 1,716,007 shares of the company’s stock valued at $10,021,000 after purchasing an additional 304,326 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in DarioHealth by 7.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 36,948 shares of the company’s stock valued at $216,000 after purchasing an additional 2,712 shares during the period. Renaissance Technologies LLC purchased a new position in shares of DarioHealth during the 1st quarter worth approximately $357,000. Finally, State Street Corp grew its holdings in shares of DarioHealth by 2.9% during the 1st quarter. State Street Corp now owns 333,544 shares of the company’s stock worth $1,948,000 after acquiring an additional 9,301 shares during the period. Institutional investors own 49.01% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Cowen reduced their target price on DarioHealth from $18.00 to $14.00 and set an “outperform” rating on the stock in a report on Tuesday. Alliance Global Partners raised DarioHealth from a “neutral” rating to a “buy” rating and set a $8.75 target price on the stock in a research report on Friday, May 13th. Finally, Cowen lowered their price target on DarioHealth from $18.00 to $14.00 and set an “outperform” rating on the stock in a research report on Tuesday. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $15.44.

About DarioHealth

(Get Rating)

DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems.

See Also

Earnings History for DarioHealth (NASDAQ:DRIO)

Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.